


Third Quarter 2020 Results Call

Corporate Update & Financial Results

November 5, 2020



Forward-Looking Statements

BioCryst's presentation may contain forward-looking statements, including statements regarding future results, unaudited and forward-looking financial information and company performance or achievements. These statements are subject to known and unknown risks and uncertainties which may cause our actual results, performance or achievements to be materially different from any future results or performances expressed or implied in this presentation. You should not place undue reliance on the forward-looking statements. For additional information, including important risk factors, please refer to BioCryst's documents filed with the SEC and located at <http://investor.shareholder.com/biocryst/sec.cfm>

Agenda

- ◆ Corporate Update:

Jon Stonehouse – President and Chief Executive Officer

- ◆ ORLADEYO™ (berotralstat) Launch Readiness:

Charlie Gayer – Chief Commercial Officer

Megan Sniecinski – Chief Business Officer

- ◆ BCX9930 Update

Dr. Bill Sheridan – Chief Medical Officer

- ◆ Financial Update

Anthony Doyle – Chief Financial Officer

- ◆ Summary and Q&A




Corporate Update:

Jon Stonehouse

President and Chief Executive Officer

Multiple Upcoming Program Updates





ORLADEYO™ (berotralstat) Launch Readiness:

Charlie Gayer – Chief Commercial Officer

Megan Sniecinski – Chief Business Officer

Coming Soon: Orladeyo™

Orladeyo™
(berotralstat) 150 mg capsule



Recent and Upcoming Publications Support Launch

APeX-2 Trial



American College of Allergy, Asthma & Immunology (ACAAI) 2020 Annual Scientific Meeting

November 13-15, 2020

Distinguished Industry Oral Abstract:

- *Bertralstat Reduces Attacks in Patients with Hereditary Angioedema (HAE): APeX-2 Trial 48 Week Results*

Posters:

- *Bertralstat Improves Patient-Reported Quality of Life Through 48 Weeks in the Phase 3 APeX-2 Trial*
- *Bertralstat Positively Impacts Patient-Reported Satisfaction: Results from the Phase 3 APeX-2 trial*
- *Patient Perspectives on the Treatment Burden of Injectable Medication Administration for Hereditary Angioedema*
- *Prophylactic Treatment Burden: Assessment by Caregivers of Patients with Hereditary Angioedema*
- *Understanding Differences in Perceptions of Hereditary Angioedema Treatment Burden May Improve Patient-Physician Treatment Care Dialogue*




Clinical Update:

Dr. Bill Sheridan – Chief Medical Officer

Factor D: An Outstanding Drug Target for Complement-mediated Diseases

- Factor D is essential to initiate the Alternative Pathway
- Blocking Factor D blocks the Alternative Pathway and all downstream products



Spectrum of Alternative Pathway Dysregulation Diseases

Hematology

PNH

paroxysmal nocturnal hemoglobinuria

aHUS

atypical hemolytic uremic syndrome

Rheumatology

ANCA vasculitis

antineutrophil cytoplasmic antibody-associated vasculitis

Lupus nephritis

IgAN vasculitis

Nephrology

C3G

glomerulonephritis


PMN

primary membranous nephropathy

IgAN

IgA nephropathy

Oral Monotherapy with BCX9930 Offers Advantage of Controlling Both Intravascular (IVH) and Extravascular (EVH) Hemolysis





Financial Update:

Anthony Doyle— Chief Financial Officer

Cash position & 2020 guidance (in millions)

Cash, cash equivalents, restricted cash & investments at December 31, 2019	\$138
Cash, cash equivalents, restricted cash & investments at September 30, 2020	\$149
Senior credit facility ^A	\$46
REVISED FY 2020 GUIDANCE	
Net operating cash utilization	\$150-165
Operating expenses ^A	\$180-195

^A - Excludes equity-based compensation.

Thank You...

Questions and Answers

